Pacific Edge Ltd has now substantially completed a commercial agreement with the Southern District Health Region (SDHR) for the use of its non-invasive Cxbladder genomic biomarker tests.
Under the primary care model, General Practitioners will be able to order Cxbladder Triage to help safely de-intensify clinical workup for patients presenting with hematuria, which may reduce the need for secondary referral and an invasive cystoscopy.
The agreement means that 15 of New Zealand’s 20 administrative health regions, covering more than 75% of the population, will now have access to the test via public healthcare.
See more
